The aromatase inhibitor anastrozole inhibits estrogen synthesis. Fulvestrant binds and accelerates degradation of estrogen receptors. We hypothesized that these two agents in combination might be more ...

Phase II trial of paclitaxel and cisplatin in women with advanced breast cancer: an active regimen with limiting neurotoxicity. The median follow-up duration was approximately 6 months. The estimated ...

Double-Blind, Randomized Trial Comparing the Efficacy and Tolerability of Fulvestrant Versus Anastrozole in Postmenopausal Women With Advanced Breast Cancer Progressing on Prior Endocrine Therapy: ...

We previously reported prolonged progression-free survival and marginally prolonged overall survival among postmenopausal patients with hormone receptor–positive metastatic breast cancer who had been ...

A study by researchers from Queen Mary University of London shows that bone loss known to be associated with the use of the breast cancer prevention drug Anastrozole partially reverses, particularly ...

Share on Pinterest Anastrozole can reduce breast cancer risk after menopause, but does it come with its own risks? Image credit: shironosov/Getty Images. A drug used as a breast cancer treatment has ...

Study author Jack Cuzick, MD, Queen Mary University, London, United Kingdom, explained that another endocrine therapy, tamoxifen, has previously been demonstrated to have a similar extended effect in ...

Compared with anastrozole alone, the combination of fulvestrant and anastrozole significantly improved time without disease progression and extended the median overall survival of women with endocrine ...

The effect of anastrozole on peripheral and tumour aromatase activity and oestrogen levels in postmenopausal patients with oestrogen receptor-rich breast tumours was investigated. Twenty-six patients ...

The Queen Mary University of London professor leading an international breast cancer study says anastrozole—rather than tamoxifen—should be the preventive drug-of-choice for post-menopausal women at ...